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ABSTRACT
Introduction Our aim was to assess the effect of 
introducing flash monitoring in adults with type 1 diabetes 
with respect to change in hemoglobin A1c (HbA1c) and 
frequency of hospital admissions.
Research design and methods Prospective 
observational study of adults with type 1 diabetes in our 
center, in whom a prescription for a flash monitoring 
sensor was collected. Primary outcome was change in 
HbA1c between 2016 and after flash monitoring. Rates of 
hospital admission were compared between the first year 
after flash monitoring and the corresponding 12- month 
period 2 years earlier.
Results Approximately half of all adults with type 1 
diabetes, attending our center, collected prescriptions for 
flash monitoring sensors (n=2216). Median fall in HbA1c 
was −1 (−0.1) mmol/mol (%) (p<0.001) and was greatest 
in those with baseline HbA1c >75 (9.0) mmol/mol (%): 
−10 (−0.9) mmol/mol (%), p<0.001. 43% of those with 
a baseline HbA1c >53 mmol/mol (7%) experienced a 
≥5 mmol/mol (0.5%) fall in HbA1c. In addition to higher 
HbA1c, early commencement within 1 month of NHS- 
funded flash monitoring (p<0.001), and male gender 
(p=0.013) were associated with a fall in HbA1c of ≥5 (0.5) 
mmol/mol (%). Socioeconomic deprivation (p=0.009) and 
collecting fewer than 2 sensors per month (p=0.002) 
were associated with lack of response. Overall, hospital 
admissions did not change but an increase in admissions 
for hypoglycemia was observed (1.1% vs 0.3%, p=0.026).
Conclusions Flash monitoring is associated with 
reduction in HbA1c in individuals with HbA1c >58 mmol/
mol. Numerous clinical features are independently 
associated with HbA1c response. An increase in 
hypoglycemia admissions occurred following flash 
monitoring.
INTRODUCTION
Flash glucose monitoring is a form of inter-
stitial glucose monitoring which is distinct 
from conventional continuous glucose 
monitoring (CGM) in only providing a 
glucose result when the sensor is scanned 
by a reader. It does not provide alarm func-
tions but in other respects, such as trend 
arrows and 24 hours glucose trace, it is similar 
to conventional CGM.1 Flash monitoring 
was first made available in the UK in 2015, 
although prior to November 2017, all use 
was by self- funding individuals. Self- funders 
tended to be more affluent than the general 
population of people with type 1 diabetes 
and had lower hemoglobin A1c (HbA1c).2 
The only large randomized study of flash 
monitoring was limited to a population with 
HbA1c ≤58 mmol/mol (7.5%) and no signifi-
cant issues with hypoglycemia awareness. This 
study demonstrated a significant reduction in 
sensor detected hypoglycemia with no change 
in HbA1c but is difficult to generalize to the 
majority of people with type 1 diabetes.3 We 
have previously reported a prospective obser-
vational study of the first 900 individuals with 
type 1 diabetes commenced on flash moni-
toring in our center, showing substantial 
Significance of this study
What is already known about this subject?
 ► Flash monitoring reduces hypoglycemia in adults 
with well- controlled type 1 diabetes and, in real- 
world studies, is associated with reductions in he-
moglobin A1c (HbA1c).
What are the new findings?
 ► Individuals most motivated to commence flash mon-
itoring early had significantly greater reductions in 
HbA1c as did those with lower deprivation and high-
er levels of sensor use.
 ► More hospital admissions with hypoglycemia oc-
curred following flash monitoring.
How might these results change the focus of 
research or clinical practice?
 ► Flash monitoring is an effective intervention but pre-
dictors of non- response may be able to help better 
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improvements in HbA1c and reduction in admissions for 
diabetic ketoacidosis (DKA).4 However, this was not repli-
cated in a prospective assessment of flash monitoring in 
Belgium.5 Assessments of flash monitoring to date have 
typically focused on the early adopters of this technology6 
and cannot be extrapolated to the wider cohort of people 
with type 1 diabetes. We now present the largest prospec-
tive single- center evaluation of the introduction of flash 
monitoring, with respect to HbA1c and hospital admis-
sions, encompassing almost half the population with type 
1 diabetes in our clinics.
PARTICIPANTS AND METHODS
Study design and participants
We conducted a prospective observational study of all 
adults with type 1 diabetes, who collected a National 
Health Service (NHS) prescription for Freestyle Libre 
sensors (Abbott, Witney, UK) between February 2018 and 
February 2019 within NHS Lothian health board. NHS 
Lothian provides care to approximately 800 000 individ-
uals, including 4671 with type 1 diabetes. NHS Lothian 
funding for flash monitoring was introduced in February 
2018 using Scottish Diabetes Group eligibility criteria: 
(1) intensive insulin therapy; (2) agree to attend a flash 
monitoring education session; (3) agree to scan glucose 
levels at least six times per day; (4) agree to share glucose 
data with their clinic and (5) had attended a diabetes 
structured education programme or demonstrated 
equivalent self- management knowledge. In February 
2018, all people with type 1 diabetes attending our clinics 
were sent a letter detailing these criteria and, if eligible, 
how to obtain NHS- funded sensors. All individuals who 
commenced NHS- funded flash monitoring attended a 
1- hour education session. The study was entirely obser-
vational (with no deviation from standard clinical care) 
and ethics approval was not required.
Outcomes
The primary outcome was change in HbA1c between 2016 
and the next available HbA1c following first prescription 
of sensors (at least 4 weeks after commencement). The 
year 2016 was chosen as the baseline HbA1c, as a signifi-
cant proportion of individuals had used flash monitoring 
on a self- funded basis prior to NHS prescription, there-
fore choosing a later baseline date had the potential 
to underestimate the HbA1c effect of flash monitoring 
introduction. Paired HbA1c data were available in 92.7% 
(1800/1941), where a 2016 baseline value was available. 
We also reported the proportion of individuals achieving 
the Scottish HbA1c target (<58 mmol/mol (7.5%)) 
and National Institute for Health and Care Excellence 
(NICE) target (≤48 mmol/mol (6.5%)) (https://www. 
nice. org. uk/ guidance/ ng17). In addition, we assess 
predictors of an HbA1c response (defined as a fall in 
HbA1c of ≥5 mmol/mol (0.5%)) both in the complete 
cohort and in a cohort where HbA1c was >53 mmol/mol 
(7.0%) at baseline (arguably representing the threshold 
level at which HbA1c lowering would be regarded as clin-
ically appropriate).
We sought to include as many potential predictors of 
HbA1c response as possible, including Scottish Index 
of Multiple Deprivation 2016 (SIMD) rank and quintile 
(https:// www2. gov. scot/ Topics/ Statistics/ SIMD). The 
structured education programme offered in our center 
is Dose Adjustment for Normal Eating (DAFNE)7 and 
previous participation was discerned from our national 
clinic database system, SCI- Diabetes (https://www. sci- 
diabetes. scot. nhs. uk). Mode of insulin delivery (multiple 
daily injection) or continuous subcutaneous insulin 
infusion (CSII)) was also obtained from SCI- Diabetes. 
Prescribing data were obtained from NHS Lothian 
Prescribing Analytical Services, using the individuals 
unique NHS Scotland identifier (Community Health 
Index number), and reflected the number of sensors 
and glucose test strips collected per month from NHS 
prescriptions in NHS Lothian. Frequency of flash moni-
toring scanning was obtained from the LibreView portal 
in a subset of individuals (n=407).
Hospital admission statistics were obtained for the first 
12 months following initial flash monitoring prescription 
(from our health board’s analytical services department) 
and were compared with the corresponding 12- month 
window starting in 2016, in individuals diagnosed with 
diabetes prior to 2016 (n=1590).
Statistical analysis
Data were mostly non- normally distributed (as deter-
mined by Shapiro- Wilk test) and are presented as median 
and IQR. Paired data were analyzed by Wilcoxon signed- 
rank test and unpaired data by Mann- Whitney U test. 
Comparisons across multiple groups were analyzed by 
Kruskal- Wallis test. Categorical data were compared 
by χ2 test or by McNemar test, when comparing paired 
repeated measurements. Logistic regression was 
performed to identify independent predictors of HbA1c 
response. Correlations were analyzed by Spearman’s rank 
correlation. Significance was accepted at p<0.05. All anal-




Approximately 47% of all adults with type 1 diabetes in 
Lothian collected a prescription for flash monitoring 
sensors (n=2216). A summary of clinical and demo-
graphic characteristics for the cohort are presented in 
table 1. Thirty- eight per cent (n=835) obtained their first 
prescription in the month following NHS funding being 
introduced (described as ‘early start’) (table 1). Early 
start individuals were older (46 (33–57) vs 43 (30–55) 
years, p<0.001), more affluent (SIMD rank 4682 (2663–
6337) vs 4321 (2570–6061), p=0.013), had lower baseline 
HbA1c (61 (55–70) vs 64 (55–74) mmol/mol, p<0.001) 
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completed DAFNE (41% vs 28%, p<0.001), more likely to 
be CSII users (28% vs 17%, p<0.001) and previously tested 
capillary blood glucose more frequently (3.3 (1.9–5.5) vs 
3.0 (1.1–4.7) test strips per day, p<0.001), compared with 
those who started flash monitoring later. Early start indi-
viduals were more likely, when using flash monitoring, 
to scan ≥9 times per day (the median frequency in this 
cohort) (65% vs 43%, p=0.008).
Overall change in HbA1c
Median duration from first flash monitoring prescrip-
tion to next HbA1c was 38 (IQR 24–51) weeks. In total, 
the median change in HbA1c was −1 mmol/mol (IQR 
−8–5, p<0.001) (−0.1 (−0.7–0.5)%), greatest in those 
with HbA1c >75 (9.0) mmol/mol (%) at baseline (−10 
(−22–0), p<0.001) (−0.9 (−2.0–0.0)%) compared with 
those with baseline HbA1c 58 (7.5)–75 (9.0) mmol/
mol (%) (−2 (−8–3), p<0.001) (−0.2 (−0.7–0.3) and 
baseline HbA1c <58 (7.5) mmol/mol (%) (+2 (−2–8), 
p<0.001) (+0.2 (−0.2–0.7)) (p<0.001 for comparison 
between baseline groups). In individuals with a baseline 
HbA1c ≥58 mmol/mol, the median change in HbA1c was 
−4 mmol/mol (−11–2) (−0.4 (−1–0.2). The percentage of 
individuals with HbA1c <58 (7.5) mmol/mol (%) rose 
from 34% (613/1800) in 2016 to 40% (711/1800) after 
commencement of flash monitoring (p<0.001). The 
percentage of individuals with HbA1c >75 (9.0) mmol/
mol (%) fell from 19% (342/1800) to 15% (276/1800) 
(p<0.001) (figure 1). The percentage with HbA1c ≤48 
(6.5) mmol/mol (%) rose from 10% (182/1661) to 12% 
(212/1661) (p=0.057).
Prescribing data
In the complete cohort, median sensors collected per 
month was 2.3 (2.0–2.7) with 16% collecting fewer than 
two sensors per month (349/2216) and a discontinuation 
Table 1 Clinical and demographic characteristics of the 
cohort
Median (IQR) or % n
Age (years) 44.3 (31.2–56.0) 2216
Female 49.0 1086
Male 51.0 1130
Age at diagnosis (years) 19.4 (10.6–30.7) 2199
Duration of diabetes (years) 19.4 (11.5–31.5) 2199
HbA1c 2016 (mmol/mol) 62 (55–72) 1941
HbA1c 2016 (%) 7.8 (7.2–8.7)
SIMD rank (out of 6976) 4449 (2594–6183) 2151
SIMD quintile 1 8.5 188
SIMD quintile 2 18.8 416
SIMD quintile 3 17.5 388
SIMD quintile 4 18.0 399
SIMD quintile 5 34.3 760
SIMD data not available 2.9 65
Start 1 (February and March 
2018)
37.7 835
Start 2 (April 2018) 19.0 421
Start 3 (May–June 2018) 14.3 316
Start 4 (July–September 
2018)
12.8 284
Start 5 (October 2018–
February 2019)
16.2 360
Completed DAFNE 32.5 721
CSII user 21.3 472
CSII, continuous subcutaneous insulin infusion; DAFNE, Dose 
Adjustment for Normal Eating; HbA1c, hemoglobin A1c; SIMD, 
Scottish Index of Multiple Deprivation.
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rate of 8.9% (182/2043), defined as no collected prescrip-
tions in the final 3 months of follow- up. Individuals in 
the early start cohort were less likely to have collected 
fewer than two sensors per month (13% vs 17%, p=0.006) 
and less likely to have discontinued flash monitoring 
use (7.2% vs 10.1%). Limiting the assessment to those 
diagnosed with diabetes prior to 2017, the median daily 
glucose test strip prescription in the first 6 months of 2017 
was 3.3 (IQR 1.6–4.9) falling to 0.8 (0.3–2.2) following 
commencement of flash monitoring (p<0.001).
Univariate analysis of change in HbA1c
Higher baseline HbA1c was strongly associated with 
greater fall in HbA1c (R −0.427, p<0.001) (figure 2). In 
addition, male gender, lower socioeconomic deprivation, 
commencement in the first month after NHS funding 
became available, collecting two or more sensors per 
month and attendance at DAFNE were all associated 
with greater fall in HbA1c in univariate analysis (table 2). 
In the early start cohort (February and March 2018), 
the percentage with HbA1c <58 (7.5) mmol/mol (%) 
rose from 36% (269/751) to 45% (341/751) (p<0.001), 
however there was no significant difference in those in 
later start cohorts (33% (344/1049) vs 35% (370/1049), 
p=0.118). Similarly, the change in HbA1c after flash moni-
toring was +1 (+0.1) mmol/mol (%) (−8–8 (−0.7–0.7), 
p=0.572) in individuals in SIMD quintile 1 compared 
with −1 (−0.1) mmol/mol (−8–5 (−0.7–0.5), p<0.001) in 
those in SIMD quintiles 2–5.
Logistic regression analysis of change in HbA1c
In total, 37% (668/1661) achieved an HbA1c fall of ≥5 
(0.5) mmol/mol (%), with a higher proportion noted 
in those with baseline HbA1c ≥53 (7.0) mmol/mol 
(%) (43% (633/1474)) and baseline HbA1c ≥58 (7.5) 
mmol/mol (%) (47% (553/1187)). Fall in HbA1c of 
≥5 (0.5) mmol/mol (%) was independently associated 
with higher HbA1c, early commencement of flash moni-
toring, collecting two or more sensors per month, lower 
socioeconomic deprivation and male gender (table 3). 
When limited to those with an HbA1c ≥53 (7.0) mmol/
mol (%) at baseline, younger age was also independently 
associated with fall in HbA1c (table 3).
Hospital admission data
The percentage of individuals admitted to hospital in 
the 12 months following flash monitoring was not signifi-
cantly different when compared with the corresponding 
12- month period 2 years earlier (19% vs 17%, p=0.151). 
However, the total number of admission episodes was 
Figure 2 Relationship between baseline hemoglobin A1c 
(HbA1c) (2016) and subsequent change in HbA1c following 
flash monitoring. The gray shading indicates the 95% CI for 
the regression line. Spearman’s r=−0.427, p<0.001.
Table 2 Univariate analysis of median change in HbA1c 
between 2016 and following flash monitoring prescription 
(mmol/mol and %)
Change in HbA1c n P value
Male −2 (−8–4) 900
−0.2 (−0.7–0.4)
Female −1 (− 8–6) 900 0.015
−0.1 (−0.7–0.6)
CSII −1 (−6–4) 1360
−0.1 (−0.6–0.4)
MDI −1 (−9–5) 440 0.246
−0.1 (−0.8–0.5)
SIMD quintile 1 +1 (−8–8) 145
+0.1 (−0.7–0.7)
SIMD quintile 2–5 −1 (−8–5) 1611 0.021
−0.1 (−0.7–0.5)






−1 (−8–6) 1049 0.013
−0.1 (−0.7–0.6)






target at baseline 
(≥58 mmol/mol 
(7.5%))
−4 (−11–2) 1187 <0.001
−0.4 (−1.0–0.2)
DAFNE −2 (−8–4) 644
−0.2 (−0.7–0.4)
No DAFNE −1 (−8–5) 1156 0.033
−0.1 (−0.7–0.5)




Fewer than two 




Data are median (IQR).
CSII, continuous subcutaneous insulin infusion; DAFNE, 
Dose Adjustment for Normal Eating; HbA1c, hemoglobin A1c; 
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greater (582 vs 490 admissions, p=0.044). The percentage 
of individuals with an admission for DKA was 1.8% in the 
12 months following flash monitoring compared with 
2.6% 2 years earlier (p=0.118). The total number of DKA 
admissions was also not significantly different (36 vs 49, 
p=0.143). When stratified by start cohort, there was a 
significant DKA reduction in the early start group (7 vs 
18 individuals, p=0.046) compared with later starts (22 
vs 28 individuals, p=0.417). The proportion of people 
admitted due to hypoglycemia was small (1.1%) but was 
greater than 2 years previously (0.3%, p=0.006). The total 
number of hypoglycemia admissions was also greater in 
the year following flash monitoring (17 vs 5, p=0.014). 
Prior attendance at a DAFNE course was associated with a 
lower risk of being admitted for hypoglycemia in the year 
after flash monitoring prescription (OR 0.23, p=0.040). 
No other clinical or demographic factors were associated 
with risk of hypoglycemia admission.
DISCUSSION
We have demonstrated that flash monitoring is associated 
with significant reductions in HbA1c in people with type 1 
diabetes, although this is largely confined to people with 
HbA1c >58 (7.5) mmol/mol (%) at baseline. The magni-
tude of change in the total cohort (−1 (−0.1) mmol/
mol (%)) is not as great as demonstrated in our previous 
assessment of flash monitoring (−4 (−0.4) mmol/mol 
(%)), which was limited to the earliest adopters of NHS- 
funded flash monitoring (corresponding to the early 
start group in this study).4 Commencement of flash 
monitoring at the earliest opportunity after NHS funding 
was introduced, was a significant independent predictor 
of an HbA1c fall of ≥5 (0.5) mmol/mol (%). Early 
commencement of flash monitoring was associated with a 
number of parameters which are typically associated with 
lower HbA1c, such as CSII use,8 DAFNE attendance7 and 
lower socioeconomic deprivation.9 However, the asso-
ciation of early flash monitoring commencement and 
HbA1c response was independent of these parameters 
and suggests that the individual’s motivation to use this 
technology is critical. Early flash monitoring users had 
a higher utilization of glucose test strips prior to flash 
monitoring and were also more likely to scan frequently 
when using flash monitoring, suggesting more intensive 
self- management in this group, both at baseline and 
during flash monitoring use.
Socioeconomic deprivation has a clear negative influ-
ence on the likelihood of HbA1c falling after flash moni-
toring commencement, greatest for those in the most 
deprived SIMD quintile. Socioeconomic deprivation is 
therefore a predictor of suboptimal HbA1c9 and reduces 
the likelihood of benefiting from flash monitoring. It may 
be the case that socioeconomic deprivation is a proxy for 
poorer numeracy skills, which are associated with higher 
HbA1c and may limit the usefulness of the profusion of 
new data generated from flash monitoring.10 It is also 
likely that other life challenges faced by those in the most 
deprived socioeconomic groups produce barriers to 
glycemic management which are not addressed by access 
to glucose data. These findings should prompt reflection 
on how best to support this cohort to maximize the bene-
fits of flash monitoring.
As previously demonstrated,4 the largest flash moni-
toring benefits, in terms of HbA1c reduction, were real-
ized by those with the highest baseline HbA1c. There 
was actually a significant increase in HbA1c in those with 
baseline HbA1c below 58 (7.5) mmol/mol (%). The data 
available in this study did not permit us to assess potential 
reductions in hypoglycemia and improvement in hypogly-
cemia awareness, which may have been the primary goal 
Table 3 Logistic regression analysis of factors influencing HbA1c response (fall of of ≥5 mmol/mol (0.5%)) following 
commencement of flash monitoring
All individuals with type 1 diabetes 
(n=1741)
Individuals with baseline HbA1c 
≥53 mmol/mol (7.0%) (n=1428)
OR 95% CI P value OR 95% CI P value
HbA1c below 65 mmol/mol (8.1%) 0.25 0.20 to 0.31 <0.001 0.35 0.28 to 0.43 <0.001
Early flash monitoring start (first prescription in 
February or March 2018)
1.46 1.18 to 1.81 <0.001 1.38 1.10 to 1.74 0.005
Age (per year increment) 0.162 0.011 to 2.320 0.180 0.986 0.977 to 0.994 0.001
Age at diagnosis (per year increment) 6.14 0.43 to 88.64 0.182 1.01 1.00 to 1.02 0.091
Fewer than two sensors per month collected 0.62 0.45 to 0.84 0.002 0.63 0.45 to 0.86 0.005
SIMD 1 (most deprived quintile) 0.60 0.40 to 0.88 0.010 0.60 0.40 to 0.90 0.014
Male 1.31 1.06 to 1.62 0.013 1.29 1.03 to 1.62 0.026
DAFNE 1.15 0.93 to 1.44 0.202 1.14 0.90 to 1.43 0.277
CSII 0.90 0.70 to 1.16 0.416 0.93 0.71 to 1.22 0.615
Analysis presented for the complete cohort and also when limited to those with HbA1c >53 mmol/mol (7.0%) at baseline.
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in many individuals with lower baseline HbA1c. Observa-
tional studies are unlikely to fully resolve this issue and 
only a randomized controlled trial, in a genuinely repre-
sentative population with type 1 diabetes, could offer 
conclusive evidence of hypoglycemia reduction. Inter-
estingly, a recent large prospective observational study 
in Belgium has shown reduced rates of hypoglycemia in 
flash monitoring users but little effect on HbA1c.5 These 
differences may reflect the slightly higher mean HbA1c 
in our cohort (65 mmol/mol (8.1%) vs 62 mmol/mol 
(7.8%)) as well as lower baseline rates of hospital admis-
sion for hypoglycemia in our population (0.3% vs 1.9%), 
therefore the primary focus of therapy may have been 
skewed toward HbA1c reduction rather than hypogly-
cemia avoidance.
Older age at flash monitoring commencement was 
independently associated with a lower likelihood of 
HbA1c response. This contrasts with the JDRF study of 
CGM, which demonstrated maximum HbA1c lowering 
in older adults.11 The association between male gender 
and glycemic response to flash monitoring has not, to 
our knowledge, been previously reported and is diffi-
cult to explain. Men had marginally lower levels of test 
strip use prior to flash monitoring use but this did not 
appear to influence the association and, comparing men 
and women, flash monitoring daily scanning trended 
toward being higher in women (data not shown). It is not 
surprising to find that individuals in whom fewer than 
two sensors were collected per month (the minimum 
number to ensure complete flash monitoring coverage) 
were less likely to see a substantial reduction in HbA1c. 
This is consistent with previous studies of CGM which 
demonstrate a relationship between percentage sensor 
use and reduction in HbA1c.11
Glucose test strip prescribing fell significantly following 
commencement of flash monitoring, as would be 
expected. The approximate threefold reduction in test 
strip prescribing will offset some of the excess healthcare 
expenditure associated with flash monitoring. Glucose 
test strip use may fall further following changes to UK 
driving regulations, which now permit the use of flash 
monitoring glucose in most circumstances (https://www. 
gov. uk/ guidance/ diabetes- mellitus- assessing- fitness- to- 
drive# insulin- treated- diabetes).
The slight increase in total admissions, following flash 
monitoring, is potentially attributable to the greater 
likelihood of admission as the cohort ages. The smaller 
number of DKA admissions following flash monitoring 
did not reach statistical significance. This is in contrast 
to the findings in our earlier publication which focused 
on the earliest cohort of flash monitoring users and did 
suggest a decrease in rates of DKA.4 Indeed, within the 
current study cohort, those in the early start group had 
a significant reduction in DKA admissions not replicated 
in later users. Whether flash monitoring has a significant 
impact on DKA may only become clear on assessment of 
larger national cohorts.
Admissions for hypoglycemia were rare but increased 
significantly following flash monitoring. While hospital 
admission data for severe hypoglycemia fail to capture the 
majority of episodes,12 our findings are consistent with the 
observation that real- time CGM is superior to flash moni-
toring in reducing hypoglycemia in high- risk individuals.13
An assessment of the effect of CGM on hospital 
admissions in Belgium showed CGM to be effective in 
a population with high rates of impaired awareness of 
hypoglycemia (47%) and glucose- related hospital admis-
sions (16%).14 Although this was a substantially different 
cohort from the one reported in our study, it does raise 
the question of whether alarms are necessary, where 
hypoglycemia reduction is the primary goal of therapy. 
However, a subsequent Belgian assessment of flash moni-
toring was associated with lower rates of self- reported 
severe hypoglycemia and a non- significant decrease 
in hypoglycemia hospital admissions.5 Our study was 
limited by the absence of detailed information on hypo-
glycemia awareness and hypoglycemia event rates. Inter-
estingly, the only factor which predicted an admission for 
hypoglycemia in flash monitoring users was not having 
attended a DAFNE course. DAFNE is known to reduce 
rates of severe hypoglycemia as well as improving hypo-
glycemia awareness15 and our observation reinforces the 
importance of adequate self- management education in 
conjunction with new technologies.
The key strength of this study is the large number of indi-
viduals assessed, making it the largest prospective report 
of HbA1c change following flash monitoring to date. As a 
single- center study, we have been able to report comprehen-
sive data on HbA1c monitoring and hospital admissions. On 
the other hand, a single- center assessment is open to ques-
tions of generalizability, although our clinic demographics 
are transparently similar to other centers within the UK. 
This study is also open to the typical criticisms of obser-
vational studies, including whether the observed changes 
in HbA1c can be attributed to flash monitoring. We have 
addressed this criticism in an earlier publication where we 
were able to show that individuals within our center never 
exposed to flash monitoring did not show any significant 
reduction in HbA1c across the same period.4 We did not 
have detailed information on potential self- funded use of 
flash monitoring, within our cohort, prior to NHS funding 
becoming available, we therefore made a pragmatic deci-
sion to use 2016 HbA1c data as baseline. This was based on 
an earlier study4 showing that a significant proportion of 
our patients were self- funding in 2017 and using these data 
as baseline would lead to a significant underestimate of 
the impact of flash monitoring. Another limitation of our 
study, as noted earlier, is that reliance on hospital admis-
sions to capture severe hypoglycemia will have resulted in 
a significant underestimation of total severe hypoglycemic 
episodes.
We have shown that flash monitoring is associated with 
significant improvements in HbA1c, largely confined to 
those with above target HbA1c at baseline. The magni-
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in previous reports and may be explained by the fact 
that early adoption of this technology is a predictor of 
benefit. Unlike this study, previous reports have largely 
been limited to early flash monitoring users and may not 
be generalizable to all individuals with type 1 diabetes.4 6 
Although the observational study design cannot confirm 
flash monitoring as the cause for change in HbA1c, we 
have previously shown that individuals not exposed to 
flash monitoring, in our center, had no change in HbA1c 
across a similar time scale.4 We present a number of other 
factors associated with HbA1c lowering in flash moni-
toring users, although none is sufficiently predictive to 
justify limiting the use of flash monitoring to particular 
cohorts. These factors do, however, suggest areas where 
resources could be directed to ensure the benefits of flash 
monitoring are realized equitably. Patterns of hospital 
admission following flash monitoring use suggest a small 
but significant increase in severe hypoglycemia and a 
trend toward reduced DKA, although this would benefit 
from validation in larger cohorts.
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